Everyone’s New Pharma Lane Runs Through Heathrow
Two carriers built new pharma lanes in five weeks. Both end at Heathrow, an airport that lost a day to one transformer fire in March 2025.
Athithi Verma
MHRA Puts Microbiome Medicines Inside the Existing Framework While the EU Builds a Separate One
No bespoke regime is coming. Microbiome medicines meet the standard biological bar in the UK, while the EU builds a separate SoHO framework.
PDUFA VIII Keeps Every Review Clock and Hires Four Auditors
Industry renegotiated what it pays FDA without changing what it gets. The clocks held. What expanded is the apparatus for verifying the money buys reviewers.
The First Phase 3 Win for an mRNA Cancer Therapy Arrives Without Its Numbers
The first Phase 3 win for an mRNA cancer therapy. Statistical significance was reported, effect size was not, and overall survival is still open.
Four Health Systems Automated the Prior Authorization Question, Not the Answer
The piece of the federal prior authorization mandate that shipped five months early is the piece that cannot deny anything.
Novartis Declines Canadian Reimbursement for Vanrafia Five Weeks After Health Canada Approved It
Health Canada cleared Vanrafia on a Week 36 proteinuria readout. Novartis will not take that same package into Canadian pricing review.
CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route
QuickAccess read/Oncology/Antibody CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route Athithi Verma· 19 August 2026· 2 min read· Synopulse The 60-day comment period on CMS-4215-P closed at 5pm on 17 August 2026. The proposed rule, published in the Federal Register on 16 June 2026, would codify … Read more
A Third Centiloid Scale Just Cleared. The First Two Already Disagree at the Threshold.
Cortechs.ai clears NeuroQuant PET for Centiloid amyloid quantification, entering a field where the two incumbent scales differ by more than 10 Centiloids.
OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later
Five days after Tarsus paid $450 million for a Stargardt asset reading out in 2029, the competitor got a PDUFA date of 12 February 2027.
NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard
Jazz committed $820 million at signing for an epilepsy drug with one early trial behind it. The justification is a regulatory pathway, not the data.